For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Zymeworks BC Inc (NASDAQ: ZYME) closed the day trading at $10.00 up 0.91% from the previous closing price of $9.91. In other words, the price has increased by $0.91 from its previous closing price. On the day, 2.24 million shares were traded. ZYME stock price reached its highest trading level at $10.235 during the session, while it also had its lowest trading level at $9.23.
Ratios:
For a better understanding of ZYME, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.40 and its Current Ratio is at 3.40. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 04 ’25 when EcoR1 Capital, LLC bought 196,438 shares for $11.17 per share. The transaction valued at 2,193,800 led to the insider holds 17,699,774 shares of the business.
EcoR1 Capital, LLC bought 120,770 shares of ZYME for $1,430,170 on Apr 03 ’25. The Director now owns 17,503,336 shares after completing the transaction at $11.84 per share. On Apr 02 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 74,360 shares for $11.85 each. As a result, the insider paid 881,017 and bolstered with 17,382,566 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 695768960 and an Enterprise Value of 554624896. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.19 while its Price-to-Book (P/B) ratio in mrq is 2.05. Its current Enterprise Value per Revenue stands at 7.269 whereas that against EBITDA is -4.907.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.26, which has changed by 0.068376064 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -23.32%, while the 200-Day Moving Average is calculated to be -20.91%.
Shares Statistics:
Over the past 3-months, ZYME traded about 568.30K shares per day on average, while over the past 10 days, ZYME traded about 917470 shares per day. A total of 68.96M shares are outstanding, with a floating share count of 67.30M. Insiders hold about 4.07% of the company’s shares, while institutions hold 98.07% stake in the company. Shares short for ZYME as of 1741910400 were 5415327 with a Short Ratio of 9.53, compared to 1739491200 on 3837127. Therefore, it implies a Short% of Shares Outstanding of 5415327 and a Short% of Float of 10.100000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
